PRMT1 mediates RANKL-induced osteoclastogenesis and contributes to bone loss in ovariectomized mice

[1]  Min-jung Park,et al.  Lipotoxicity-Induced PRMT1 Exacerbates Mesangial Cell Apoptosis via Endoplasmic Reticulum Stress , 2017, International journal of molecular sciences.

[2]  An-min Chen,et al.  Inhibition of PRMT5 suppresses osteoclast differentiation and partially protects against ovariectomy-induced bone loss through downregulation of CXCL10 and RSAD2. , 2017, Cellular signalling.

[3]  X. Li,et al.  Disturbed MEK/ERK signaling increases osteoclast activity via the Hedgehog-Gli pathway in postmenopausal osteoporosis. , 2016, Progress in biophysics and molecular biology.

[4]  Min-jung Park,et al.  Asymmetric dimethylarginine (ADMA) treatment induces apoptosis in cultured rat mesangial cells via endoplasmic reticulum stress activation , 2016, Cell biology international.

[5]  J. Hevel,et al.  Biochemistry and regulation of the protein arginine methyltransferases (PRMTs). , 2016, Archives of biochemistry and biophysics.

[6]  Min Young Lee,et al.  PRMT1 and PRMT4 Regulate Oxidative Stress-Induced Retinal Pigment Epithelial Cell Damage in SIRT1-Dependent and SIRT1-Independent Manners , 2015, Oxidative medicine and cellular longevity.

[7]  Shouchao Zheng,et al.  Amiloride inhibits osteoclastogenesis by suppressing nuclear factor-κB and mitogen-activated protein kinase activity in receptor activator of nuclear factor-κB-induced RAW264.7 cells. , 2015, Molecular medicine reports.

[8]  L. Xing,et al.  NF-κB-Mediated Regulation of Osteoclastogenesis , 2015, Endocrinology and metabolism.

[9]  Soo-Hyun Park,et al.  Thioredoxin-interacting protein mediates hepatic lipogenesis and inflammation via PRMT1 and PGC-1α regulation in vitro and in vivo. , 2014, Journal of hepatology.

[10]  Soo-Hyun Park,et al.  Activation of PRMT1 and PRMT5 mediates hypoxia- and ischemia-induced apoptosis in human lung epithelial cells and the lung of miniature pigs: the role of p38 and JNK mitogen-activated protein kinases. , 2013, Biochemical and biophysical research communications.

[11]  Andrew D Sharrocks,et al.  MAP kinase signalling cascades and transcriptional regulation. , 2013, Gene.

[12]  M. Bedford,et al.  Protein arginine methyltransferases and cancer , 2012, Nature Reviews Cancer.

[13]  Young-sil Yoon,et al.  Protein arginine methyltransferase 1 regulates hepatic glucose production in a FoxO1‐dependent manner , 2012, Hepatology.

[14]  P. Szodoray,et al.  Increased production of asymmetric dimethylarginine (ADMA) in ankylosing spondylitis: association with other clinical and laboratory parameters. , 2011, Joint, bone, spine : revue du rhumatisme.

[15]  T. Nabika,et al.  Relationships between dimethylarginine and the presence of vertebral fractures in type 2 diabetes mellitus , 2010, Clinical endocrinology.

[16]  L. McNamara.  Perspective on post-menopausal osteoporosis: establishing an interdisciplinary understanding of the sequence of events from the molecular level to whole bone fractures , 2010, Journal of The Royal Society Interface.

[17]  Xun Xu,et al.  PRMT-1 and DDAHs-induced ADMA upregulation is involved in ROS- and RAS-mediated diabetic retinopathy. , 2009, Experimental eye research.

[18]  Yasuhiko Iwamoto,et al.  Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  H. Blair,et al.  Estrogen inhibits RANKL-stimulated osteoclastic differentiation of human monocytes through estrogen and RANKL-regulated interaction of estrogen receptor-alpha with BCAR1 and Traf6. , 2009, Experimental cell research.

[20]  H. Lee,et al.  Selective inhibition of RANK blocks osteoclast maturation and function and prevents bone loss in mice. , 2009, The Journal of clinical investigation.

[21]  Frank Herrmann,et al.  Human protein arginine methyltransferases in vivo – distinct properties of eight canonical members of the PRMT family , 2009, Journal of Cell Science.

[22]  N. Alles,et al.  NF-kappaB functions in osteoclasts. , 2009, Biochemical and biophysical research communications.

[23]  A. Scorilas,et al.  The PRMT1 gene expression pattern in colon cancer , 2008, British Journal of Cancer.

[24]  R. Faccio,et al.  RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in mice. , 2008, The Journal of clinical investigation.

[25]  M. Covic,et al.  Protein arginine methyltransferase 1 coactivates NF-kappaB-dependent gene expression synergistically with CARM1 and PARP1. , 2008, Journal of molecular biology.

[26]  S. Richard,et al.  Arginine Methylation of the Histone H3 Tail Impedes Effector Binding* , 2008, Journal of Biological Chemistry.

[27]  S. Stoch,et al.  Cathepsin K Inhibitors: A Novel Target for Osteoporosis Therapy , 2008, Clinical pharmacology and therapeutics.

[28]  H. Prins,et al.  The clinical significance of asymmetric dimethylarginine. , 2006, Annual review of nutrition.

[29]  H. J. Kim,et al.  Osteoclast differentiation requires TAK1 and MKK6 for NFATc1 induction and NF-κB transactivation by RANKL , 2006, Cell Death and Differentiation.

[30]  Frank Herrmann,et al.  Dynamics of Human Protein Arginine Methyltransferase 1(PRMT1) in Vivo* , 2005, Journal of Biological Chemistry.

[31]  Tak W. Mak,et al.  Autoamplification of NFATc1 expression determines its essential role in bone homeostasis , 2005, The Journal of experimental medicine.

[32]  E. Schwedhelm,et al.  Determination of a reference value for NG, NG‐dimethyl‐L‐arginine in 500 subjects , 2005, European journal of clinical investigation.

[33]  J. Cooke,et al.  Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA , 2005 .

[34]  J. Cooke,et al.  Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA , 2005, Vascular medicine.

[35]  L. Joseph Melton,et al.  Perspective how many women have osteoporosis? , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[36]  F. Pixley,et al.  CSF-1 regulation of the wandering macrophage: complexity in action. , 2004, Trends in cell biology.

[37]  H. Aburatani,et al.  Nuclear Factor of Activated T-cells (NFAT) Rescues Osteoclastogenesis in Precursors Lacking c-Fos* , 2004, Journal of Biological Chemistry.

[38]  John Robbins,et al.  National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.

[39]  Elizabeth McMillan,et al.  Complexity in action , 2004 .

[40]  Sakae Tanaka,et al.  Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. , 2004, The Journal of clinical investigation.

[41]  S. Nussey,et al.  Estrogen Stimulates Dimethylarginine Dimethylaminohydrolase Activity and the Metabolism of Asymmetric Dimethylarginine , 2003, Circulation.

[42]  Hong-Hee Kim,et al.  Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. , 2003, Biochemical and biophysical research communications.

[43]  G. Karsenty.  The complexities of skeletal biology , 2003, Nature.

[44]  David L. Lacey,et al.  Osteoclast differentiation and activation , 2003, Nature.

[45]  Hiroshi Takayanagi,et al.  Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. , 2002, Developmental cell.

[46]  E. Liao,et al.  Effect of age on bone mineral density and the serum concentration of endogenous nitric oxide synthase inhibitors in rats. , 2002, Comparative medicine.

[47]  C. Allis,et al.  Methylation of Histone H4 at Arginine 3 Facilitating Transcriptional Activation by Nuclear Hormone Receptor , 2001, Science.

[48]  F. Ross,et al.  Estrogen Decreases Osteoclast Formation by Down-regulating Receptor Activator of NF-κB Ligand (RANKL)-induced JNK Activation* , 2001, The Journal of Biological Chemistry.

[49]  M. Tsujimoto,et al.  Activation of p38 mitogen‐activated protein kinase is crucial in osteoclastogenesis induced by tumor necrosis factor , 2000, FEBS letters.

[50]  B. Riggs,et al.  The mechanisms of estrogen regulation of bone resorption. , 2000, The Journal of clinical investigation.

[51]  P. Kao,et al.  Protein-arginine Methyltransferase I, the Predominant Protein-arginine Methyltransferase in Cells, Interacts with and Is Regulated by Interleukin Enhancer-binding Factor 3* , 2000, The Journal of Biological Chemistry.

[52]  Kozo Nakamura,et al.  Reciprocal Role of ERK and Nf-κb Pathways in Survival and Activation of Osteoclasts , 2000, The Journal of cell biology.

[53]  T. Hedner,et al.  Increased circulating concentrations of asymmetric dimethyl arginine (ADMA), an endogenous inhibitor of nitric oxide synthesis, in preeclampsia , 1998, Acta obstetricia et gynecologica Scandinavica.

[54]  Ulrich Siebenlist,et al.  Requirement for NF-κB in osteoclast and B-cell development , 1997 .

[55]  M. Karin,et al.  Regulation and function of the JNK subgroup of MAP kinases. , 1997, Biochimica et biophysica acta.

[56]  A. Leonardi,et al.  Requirement for NF-kappaB in osteoclast and B-cell development. , 1997, Genes & development.

[57]  E. Wagner,et al.  c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. , 1994, Science.